Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 38 clinical trials
Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

This phase III trial compares the effects of nivolumab with chemo-immunotherapy versus chemo-immunotherapy alone in treating patients with newly diagnosed primary mediastinal B-cell lymphoma (PMBCL). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells …

  • 13 May, 2022
  • 75 locations
Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia

This randomised controlled trial will determine the non-inferiority of stopping empiric antibiotics prior to absolute neutrophil count (ANC) recovery (Early Stopping) versus stopping antibiotics

  • 12 Dec, 2021
  • 1 location
PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma

Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive form of non-Hodgkin's lymphoma and shows extremely poor survival. This prospective pilot study to evaluate the efficacy and safety of long-acting aspargase (pegylated aspargase, PEG-ASP) combined with gemcitabine and oxaliplatin (PASP -Gemox) treatment in this population.

  • 22 Mar, 2021
  • 1 location
Roflumilast in Non-CF Bronchiectasis Study (2019)

This is a single-arm, open label, Phase II study of 12-week use of Roflumilast in stable-state non-cystic fibrosis bronchiectasis subjects. Bronchiectasis refers to a suppurative lung condition characterized by pathological dilatation of bronchi. The predominant aetiology of bronchiectasis in the Western population is related to cystic fibrosis (CF), which is …

  • 10 May, 2021
  • 1 location
Switch to Oral Antibiotics in Gram-negative Bacteremia (SOAB)

, central nervous system infection, terminal illness with expected survival less than 14 days, absolute neutrophil count less than 1,000/ml and hematopoietic or solid organ transplantation within the

  • 18 Apr, 2022
  • 7 locations
Phase 2 Study of Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation

This is a Phase 2, open-label, multi-center study to evaluate the efficacy and the safety/tolerability of poziotinib in seven patient cohorts for up to 603 previously treated and treatment-naïve NSCLC patients. Cohorts 3 and 4 were added with Amendment 1 and three additional cohorts were added with Amendment 2 (Cohorts …

stage iv non-small cell lung cancer
cancer chemotherapy
  • 09 Mar, 2022
  • 51 locations
A Study of Mavorixafor in Participants With Severe Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders

This Phase 1b study will determine the safety and tolerability of mavorixafor and its effect on absolute neutrophil count.

  • 11 Mar, 2022
  • 6 locations
Study Using Prebiotics to Improve Gut Microbiome Diversity After Autologous Stem Cell Transplantation

subject's choice. The intervention will begin approximately 10 days prior to stem cell infusion and will continue until the first day of neutrophil engraftment (first day absolute neutrophil count >500

  • 29 Apr, 2022
  • 1 location
Sitagliptin for Prevention of aGVHD After Alternative Donor Transplatation

absolute neutrophil count and platelets. To evaluate the incidence of CMV, EBV and other infections occurring during the 100 days post-transplant. To study non-relapse mortality (NRM) at

  • 24 Mar, 2022
  • 1 location
EXTEND EXpanding Treatment for Existing Neurological Disease

The primary goal of the Phase II EXTEND trial is to investigate the effects of open-label hydroxyurea treatment, escalated to maximum tolerated dose, for children with Sickle Cell Anemia and either conditional (170 - 199 cm/sec) or abnormal (≥200 cm/sec) Transcranial Doppler velocities. The primary endpoint will be measured after …

transcranial doppler ultrasonography
  • 24 Apr, 2022
  • 1 location